인공 심장 판막 시장 : 세계 예측(2026-2032년)

The Prosthetic Heart Valves Market is projected to grow by USD 27.76 billion at a CAGR of 11.91% by 2032.

Prosthetic heart valves are central to the treatment of severe valvular heart disease, including aortic stenosis, mitral regurgitation, tricuspid regurgitation, and valve dysfunction associated with rheumatic, degenerative, congenital, and infective etiologies. Demand is being shaped by the global rise in cardiovascular disease, population aging, improved diagnostic access, and expanding use of surgical valve replacement and transcatheter valve replacement techniques. The field spans mechanical valves, bioprosthetic valves, transcatheter aortic valve replacement devices, transcatheter mitral and tricuspid solutions, annuloplasty systems, and next-generation polymeric and tissue-engineered valve concepts. Clinical decision-making increasingly emphasizes durability, hemodynamic performance, thrombogenicity, anticoagulation requirements, patient anatomy, lifetime valve management, and suitability for redo procedures. As care pathways shift toward earlier diagnosis and less invasive interventions, the prosthetic heart valves landscape is becoming more multidisciplinary, connecting cardiology, cardiac surgery, imaging, interventional cardiology, anesthesiology, rehabilitation, and post-procedural monitoring into a coordinated valve-care continuum.

Transformative Shifts Reshaping Prosthetic Heart Valve Care

The prosthetic heart valves industry is undergoing a structural transformation driven by transcatheter technologies, lifetime disease management, and patient-specific treatment planning. Transcatheter aortic valve implantation has moved from use in inoperable and high-risk surgical candidates into broader clinical practice following randomized trial evidence and updated guideline recommendations, while transcatheter mitral and tricuspid valve repair and replacement continue to address complex anatomies that are less standardized than the aortic position. Bioprosthetic valves are gaining clinical preference in many older patients because they reduce the need for lifelong anticoagulation, whereas mechanical heart valves continue to be relevant for selected younger patients who prioritize long-term durability and can manage anticoagulation safely. Another major shift is the growing role of advanced imaging, including echocardiography, computed tomography, cardiac magnetic resonance, and fusion imaging, in valve sizing, access planning, procedural guidance, and complication reduction. Hospitals are also adopting heart-team models to align patient selection with evidence-based guidelines, procedural risk scores, frailty assessment, anatomical suitability, and long-term reintervention strategies. These shifts are expanding the emphasis from single-device performance to integrated valve programs that optimize diagnosis, intervention, follow-up, and outcomes.

Cumulative Impact of Artificial Intelligence on Prosthetic Heart Valves

Artificial intelligence is becoming increasingly relevant across the prosthetic heart valves ecosystem by improving diagnostic precision, procedural planning, workflow efficiency, and post-treatment surveillance. In echocardiography and cardiac computed tomography, AI-enabled image analysis can support valve anatomy assessment, calcification characterization, annular measurement, left ventricular function evaluation, and identification of patients who may benefit from referral to specialized valve teams. In interventional planning, machine learning models are being evaluated to predict paravalvular leak, conduction disturbances, vascular complications, prosthesis-patient mismatch, leaflet thrombosis, and need for pacemaker implantation after transcatheter procedures. AI also supports clinical operations by helping prioritize severe valvular disease cases, streamline imaging interpretation, and reduce variability in measurements that influence prosthetic valve sizing. In manufacturing and research, computational modeling, digital twins, and AI-assisted design can accelerate evaluation of leaflet stress, flow dynamics, durability risks, and thrombosis potential before clinical deployment. However, adoption depends on transparent validation, diverse training datasets, regulatory acceptance, cybersecurity controls, clinician oversight, and integration with existing imaging and electronic health record systems. The cumulative impact of AI is therefore not simply automation; it is the creation of more personalized, evidence-aligned, and reproducible prosthetic valve care pathways.

Key Regional Insights Across Global Prosthetic Heart Valve Adoption

In Asia-Pacific, growth in prosthetic heart valve procedures is supported by large aging populations, increasing recognition of degenerative valve disease, substantial rheumatic heart disease burden in several low- and middle-income settings, and expanding tertiary cardiac-care infrastructure in China, India, Japan, South Korea, Australia, and Southeast Asia. North America is characterized by high adoption of transcatheter valve therapies, robust guideline-driven heart-team pathways, strong reimbursement infrastructure, and widespread access to advanced cardiac imaging and structural heart programs, particularly for aortic valve replacement and complex mitral valve intervention. Latin America shows rising procedural capability in major urban centers, with Brazil and Mexico playing important roles, while access differences between public and private health systems continue to influence timely diagnosis and advanced valve intervention. Europe benefits from mature cardiac surgery networks, strong structural heart expertise, established clinical registries, and broad adoption of evidence-based valve guidelines, with Western Europe generally demonstrating greater procedural access than parts of Eastern Europe. The Middle East is investing in advanced cardiovascular centers, medical tourism, and specialist training, particularly in Gulf countries, while Africa faces a dual burden of rheumatic and degenerative valve disease with persistent gaps in screening, surgical capacity, catheter-based intervention availability, and long-term anticoagulation monitoring. Across all regions, the most important differentiators are not only device availability but also referral pathways, imaging capacity, multidisciplinary expertise, reimbursement models, and follow-up systems for prosthetic valve surveillance.

Key Group Insights Influencing Prosthetic Heart Valve Access

ASEAN countries present diverse prosthetic heart valve dynamics, with Singapore, Thailand, and Malaysia showing stronger access to advanced structural heart procedures, while larger populations in Indonesia, Vietnam, and the Philippines continue to expand cardiac-care infrastructure amid affordability, referral, and workforce constraints. The GCC is distinguished by significant investment in tertiary hospitals, rising cardiovascular risk factors, and growing adoption of minimally invasive valve interventions supported by specialist centers and public health funding. The European Union benefits from harmonized medical device regulation, cross-border clinical collaboration, and a strong base of academic cardiac centers, while ongoing emphasis on post-market surveillance and real-world evidence is shaping device evaluation and clinical practice. BRICS countries combine large patient populations, expanding domestic healthcare capacity, and substantial unmet need for valve disease diagnosis and treatment, particularly where rheumatic disease, late presentation, and uneven specialist distribution remain important clinical challenges. G7 countries generally have advanced reimbursement systems, high procedural expertise, and established registries that support evidence-based use of mechanical, bioprosthetic, and transcatheter heart valves. NATO member countries, many of which overlap with advanced European and North American health systems, show strong institutional capacity for cardiac care, but access still varies based on national reimbursement policies, hospital distribution, and specialist workforce availability. These group-level patterns show that prosthetic heart valve adoption is influenced by economic capacity, regulatory maturity, training systems, disease epidemiology, and the ability to sustain lifelong monitoring after implantation.

Key Country Insights in Prosthetic Heart Valve Care

The United States remains a leading environment for transcatheter and surgical prosthetic heart valve innovation due to extensive structural heart programs, clinical guideline adoption, and broad use of advanced imaging, while Canada emphasizes publicly funded access, regional centers of excellence, and careful prioritization of high-complexity procedures. Mexico is expanding valve intervention capacity in major cities, though public-private access differences remain significant. Brazil has one of Latin America's most developed cardiac surgery and interventional cardiology ecosystems, supported by major referral hospitals, while broader access varies across regions. The United Kingdom benefits from national guideline frameworks and specialist heart valve services, Germany has a strong cardiac surgery base and high procedural sophistication, France combines advanced interventional capability with structured reimbursement pathways, and Italy and Spain maintain established valve programs supported by experienced cardiac centers. Russia has expanded cardiovascular infrastructure in major urban areas, but access can vary geographically. China is rapidly strengthening structural heart capacity through hospital expansion, physician training, domestic clinical research, and wider diagnosis of calcific and rheumatic valve disease. India faces a substantial mix of rheumatic and degenerative valve disease, with leading hospitals offering advanced procedures while affordability, late diagnosis, and uneven access remain central challenges. Japan has a highly aging population and strong adoption of minimally invasive approaches for suitable patients, while Australia combines guideline-based care with specialized valve centers across major metropolitan regions. South Korea shows strong procedural expertise, advanced hospital infrastructure, and increasing use of imaging-guided structural heart interventions. Across these countries, prosthetic heart valve utilization is shaped by epidemiology, clinical evidence, reimbursement, hospital concentration, specialist training, and long-term follow-up capacity.

Actionable Recommendations for Prosthetic Heart Valve Industry Leaders

Industry leaders should prioritize evidence-based innovation that improves durability, hemodynamic performance, deliverability, and patient safety across surgical and transcatheter prosthetic heart valves. Product strategies should address lifetime valve management, including valve-in-valve feasibility, reduced thrombogenicity, minimized paravalvular leak, lower pacemaker risk, improved coronary access, and compatibility with advanced imaging workflows. Organizations should invest in physician education, proctoring, simulation-based training, and multidisciplinary heart-team support, particularly in regions where transcatheter valve programs are scaling. Expanding access also requires partnerships with hospitals and health systems to improve screening for aortic stenosis, mitral regurgitation, tricuspid regurgitation, and rheumatic valve disease, because delayed diagnosis remains a major barrier to optimal outcomes. Regulatory and clinical teams should strengthen real-world evidence generation, registry participation, post-market surveillance, and transparent reporting of durability and safety outcomes. Leaders should also build AI-ready data strategies that support imaging analytics, procedural planning, quality improvement, and remote monitoring while maintaining privacy, interoperability, and clinical accountability. Finally, emerging-market strategies should adapt to local affordability, training, infrastructure, and follow-up realities rather than relying on models designed only for high-resource cardiac centers.

Research Methodology for Evidence-Based Prosthetic Valve Insights

This executive summary is developed through a structured secondary-research approach using verified and publicly available sources, including clinical practice guidelines, peer-reviewed cardiology and cardiac surgery literature, regulatory publications, public health data, medical society statements, disease burden resources, and evidence from clinical registries where available. The methodology emphasizes triangulation across independent sources to validate trends in valve disease epidemiology, surgical and transcatheter treatment pathways, regional access differences, technology adoption drivers, and clinical outcome considerations. The analysis excludes market sizing, market share, and forecasting, focusing instead on qualitative and evidence-backed industry dynamics. Key themes are assessed through clinical relevance, regulatory maturity, healthcare infrastructure, reimbursement context, disease burden, workforce capacity, and adoption of structural heart programs. Regional, group, and country insights are interpreted through the lens of healthcare system readiness, specialist availability, diagnostic access, regulatory pathways, and continuity of post-implantation care, ensuring that conclusions reflect practical realities across both advanced and emerging healthcare settings.

Conclusion: The Future of Prosthetic Heart Valve Care

The prosthetic heart valves landscape is evolving from procedure-centered treatment toward comprehensive, technology-enabled valve disease management. Surgical valve replacement remains essential, while transcatheter solutions are expanding treatment options for patients who are older, higher risk, or anatomically suited to minimally invasive intervention. Evidence-based heart-team decision-making, advanced imaging, AI-enabled analytics, real-world outcome tracking, and stronger post-procedure surveillance are becoming critical to safe and effective adoption. Regional disparities remain substantial, particularly where rheumatic disease burden, limited diagnostic infrastructure, affordability constraints, and specialist shortages delay treatment. Industry leaders that align innovation with clinical evidence, lifetime patient management, equitable access, and local health-system needs will be best positioned to support improved outcomes in prosthetic heart valve care. The future of this field will be defined by durable devices, smarter planning, broader screening, and integrated care pathways that deliver the right valve therapy to the right patient at the right time.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Prosthetic Heart Valves Market, by Valve Type

• 7.1. Introduction
• 7.2. Mechanical
  • 7.2.1. Bileaflet
  • 7.2.2. Caged Ball
  • 7.2.3. Tilting Disc
• 7.3. Tissue
  • 7.3.1. Bovine
  • 7.3.2. Homograft
  • 7.3.3. Porcine

8. Prosthetic Heart Valves Market, by Material Type

• 8.1. Introduction
• 8.2. Metal Based Valves
• 8.3. Tissue Based Valves
• 8.4. Polymer Based Valves

9. Prosthetic Heart Valves Market, by Procedure

• 9.1. Introduction
• 9.2. Surgical Replacement
  • 9.2.1. Minimally Invasive
  • 9.2.2. Traditional Sternotomy
• 9.3. Transcatheter Valve Replacement
  • 9.3.1. Transapical
  • 9.3.2. Transfemoral

10. Prosthetic Heart Valves Market, by Application

• 10.1. Introduction
• 10.2. Aortic
• 10.3. Mitral
• 10.4. Tricuspid

11. Prosthetic Heart Valves Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
• 11.3. Hospitals

12. Prosthetic Heart Valves Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Prosthetic Heart Valves Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Prosthetic Heart Valves Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. AorTx Incorporated
• 16.3. Artivion Incorporated
• 16.4. Biotronik SE and Company KG
• 16.5. Boston Scientific Corporation
• 16.6. Braile Biomedica Industria e Comercio S.A.
• 16.7. Carvolix SA
• 16.8. Colibri Heart Valve LLC
• 16.9. Comed BV
• 16.10. Edwards Lifesciences Corporation
• 16.11. Foldax Incorporated
• 16.12. Heart Leaflet Technologies Incorporated
• 16.13. JenaValve Technology GmbH
• 16.14. Labcor Laboratorios Ltda
• 16.15. Lepu Medical Technology Beijing Company Limited
• 16.16. LivaNova Public Limited Company
• 16.17. Medtronic Public Limited Company
• 16.18. Meril Life Sciences Private Limited
• 16.19. Micro Interventional Devices Incorporated
• 16.20. MicroPort Scientific Corporation
• 16.21. NaviGate Cardiac Structures Incorporated
• 16.22. Peijia Medical Device Company Limited
• 16.23. Symetis SA
• 16.24. Teleflex Incorporated
• 16.25. Terumo Corporation
• 16.26. Transcatheter Technologies GmbH
• 16.27. TTK Healthcare Limited
• 16.28. ValveXchange Incorporated
• 16.29. Venus Medtech Hangzhou Incorporated
• 16.30. Xeltis BV